“We prepaid for everything that we get.” — Aaron Payment, tribal chairperson for the Sault Ste. Marie Tribe of Chippewa Indians, on the government’s responsibility to fund Native American medical clinics despite the budget impasse.
“There’s often concern that if the partner is involved he or she will become ‘diabetes police,’ and that would make the relationship worse.” — Paula M. Trief, PhD, of SUNY Upstate Medical University in Syracuse, New York, discussing a couples-based diabetes intervention.
“So, if there’s a peanut paste plant that’s infested with rodents and is creating foodborne illness risks for consumers, the FDA is not going to be coming out to that plant while the shutdown is going on.” — Thomas Gremillion, JD, director of food policy at the Consumer Federation of America, discussing one effect of the government shutdown.
“You need a full-time person just to be your scribe to do this work.” — Roxana Mehran, MD, of Icahn School of Medicine at Mount Sinai in New York City, on the paperwork burden of getting PCKS9 inhibitors to patients.
“Young kids didn’t find these pods were cool, but then Juul came out and presented this device that’s super cool to young people, and all of a sudden everything changed.” — Sharon McGrath-Morrow, MD, of Johns Hopkins School of Medicine, on the national “epidemic” of e-cigarettes.
“We need to fix this relatively quickly or we are going to start seeing problems down the line.” — Kathy McLaughlin, MD, of the Mayo Clinic in Rochester, Minnesota, commenting on a study showing a large group of women not following cervical cancer screening recommendations.
“The fact that the authors reported relatively few oversedation events at the dose selected says nothing about what will be experienced when clinicians inevitably give higher, more effective doses.” — Steven Meisel, PharmD, director of medication safety at Fairview Health Services on the latest safety analysis regarding sufentanil sublingual tablets.
“I think people just see that there is a benefit to having incisions that hurt less.” — Nasser Altorki, MD, of NewYork-Presbyterian and Weill Cornell Medicine in New York City, on the move toward more minimally invasive surgeries for esophageal and other cancers.
“I think that with appropriate treatment with molecular therapy, it will become increasingly common for patients with specific mutations to live quite a long time.” — Jose Pacheco, MD, of the University of Colorado Cancer Center in Aurora, commenting on a study showing a 6.8-year median overall survival in patients with stage IV ALK+ non-small cell lung cancer treated with ALK inhibitors.
“The bigger question is a chicken-and-egg one: is it that your sleep is disrupted and the Alzheimer’s proteins build up — or are the Alzheimer’s proteins being deposited in the brain disrupting sleep and that’s where the cycle gets initiated?” — Ron Petersen, MD, PhD, of the Mayo Clinic in Rochester, Minnesota, discussing study findings on deep sleep and tau pathology.